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Abstract
VOCAL FOLD COVER REPLACEMENT: IMAGING ANALYSIS OF
INTERMEDIATE AND LONG-TERM OUTCOMES
Kevin O. Juarez and Jennifer L. Long. Division of Head and Neck Surgery, University of
California Los Angeles, Los Angeles, CA. (Sponsored by Nwanmegha Young, Division
of Otolaryngology, Department of Surgery, Yale University, School of Medicine).

The voice is an important source of communication. Voice disorders, dysphonia, has an
estimated 30 percent lifetime prevalence in the United States with a significant economic
and social cost. Severe vocal fold scarring can lead to persistent dysphonia, has no
optimal treatment and negatively impacts those affected by impairing their quality of life
and general health. We propose a novel approach to treating sever vocal fold scarring by
replacing the entirety of the vocal fold mucosa with a tissue engineered implant, the cellbased outer vocal fold replacement (COVR). We hypothesized that intermediate and
long-term implantation of human stem-cell derived COVR implants would lead to
regeneration of vocal fold epithelium and lamina propria and establish an extracellular
matrix (ECM) approximating normal parameters. We aimed to assess the development of
these structures by assessing active factors in wound healing including white blood cell
presence, collagen and fibrin deposition, and glycosaminoglycan incidence. We resected
the vocal fold mucosa and implanted COVR gels, COVR gel components including a
decellularized gel scaffold (DECELL) and human-derived adipose stem-cell injection
(hASC Injection), or performed no treatment following intervention (SCAR) in 49 New

Zealand white rabbits with intermediate, 6-weeks, postoperative recovery and three
Yucatan Mini Pigs with long-term, 6 months, post-operative recovery prior to laryngeal
harvest. Vocal folds were sectioned and assessed through light microscopy, fluorescent
microscopy, and/or nonlinear scanning laser microscopy (NLSM) to assess outcomes of
the intervention. Analysis of light microscopy of the intermediate implantation groups
showed that the COVR implantation had the lowest levels of collagen deposition (50% in
COVR, 67% in DECELL, 82% in hASC Injection, and 83% in SCAR), greatest
glycosaminoglycan incidence (50% in COVR, 8% in DECELL, 9% in HASC injection,
and 25% in SCAR), equivalent white cell presence (50% in COVR, 83% in DECELL,
45% in hASC Injection, and 42% in SCAR) at laryngeal harvest. Additionally,
fluorescent microscopy showed persistence of HLA-staining cells in the COVR and
hASC Injection groups and none in the DECELL or SCAR treatment groups. NLSM
imaging of the long-term implantation of COVR showed increased collagen deposition in
the superficial lamina propria in the hASC Injection group, while the SCAR had no
change in collagen levels, and the COVR implant animal had decreased collagen levels
compared to untreated control folds. The superficial lamina propria also had increased
elastin deposition in the COVR group, decreased levels in the SCAR animal, and no
change in the hASC Injection animal. In the rabbits, COVR implantation promotes
improved healing and decreased scarring at six weeks, as evidenced by increased
glycosaminoglycan deposition and decreased collagen development. Additionally, there
is evidence of xenograph ASC grafts persist for several weeks with continued
immunomodulatory effects. Our data suggest decreases of overall elastin levels are a
more sensitive marker of fibrosis in NLSM imaging than increases in collagen levels.
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INTRODUCTION:
The voice is an important source of communicating between people. It is vitally
important for many professions in addition for typical socialization through verbal
communication. Voice disorders, or dysphonia, annually affects an estimated 1.7 percent
of population in the United States, over 5.5 million people, and has an estimated 30
percent lifetime prevalence.1,2 There is also a substantial cost to diagnosing, managing,
and treating patients with dysphonia, estimated at 12 billion dollars annually.3 The
diagnosis for a majority of these cases is acute laryngitis, however a significant portion of
dysphonia etiologies arise from benign vocal fold lesions (ie. polyps, nodules) and
malignant neoplasms.1 Patients who have damaged vocal fold tissue, either through
benign lesions, trauma, or surgical resection, can develop persistent dysphonia due to
vocal fold scarring. Severe scarring leaves those afflicted with impaired phonation
including chronically hoarse voice, vocal fatigue, and risks or ends professional careers.4
Dysphonia has been described by patients as impairing their quality of life,
impacting their work performance and employment, and has also been associated with
depression.5-9 Voice disorders have also been found to profoundly affect general health
impacting the mental, global and social health independent of and with greater
association than other life-threatening comorbid pathologies including malignancy,
pulmonary, cardiac disease.10 Thus it has been suggested that the effects of dysphonia
and subsequently the allocated budgets for treatment is lacking. To make matters worse,
treatment options for dysphonia are imperfect. In the case of severe vocal fold scarring,
there is no optimal treatment.
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Physiology of the Vocal Fold
To understand the difficulty of finding a treatment for severe vocal fold scarring,
it is important to understand the physiology of the vocal folds. The vocal folds are paired
symmetric structures within the larynx. Each vocal fold is made of three-layers: the nonkeratinized stratified squamous epithelium, lamina propria, and muscle. In the human
vocal fold, the lamina propria is subdivided into three distinct layers based on the
amounts of collagen and elastic fibers in each layer.11,12 The lamina propia layers are the
superficial, intermediate, and deep lamina propria. The superficial lamina propria has a
higher proportion of elastin and a narrow band of collagen. Whereas the intermediate and
deep layers of lamina propria together form the ‘vocal ligament’ or ‘elastic conus,’ which
has densely organized collagen.12 Other mammal vocal folds including the rabbit, pig,
and canine, common animal models used for vocal fold research, have a two-layer lamina
propria, the superficial and deep layers only.13,14 The vocal fold layers in cross-section
can be found in Figure 1.15
‘Body-cover’ theory – ‘Body’ explained
The landmark ‘body-cover’ theory, originally proposed by Hirano et al. in 1974,
describes a functional distinction of the vocal fold based on the interactions between
these two structures. In his theory, Hirano describes the ‘body’ consisting of the vocal
conus and underlying musculature, primarily the thyroarytenoid muscle, which work
together as a functional unit. The shape and structure of the ‘body’ is further influenced
by the vocalis and cricothyroid muscles, external to the vocal fold proper. This in turn,
alters the mechanical properties of the vocal folds including position, shape, and tension,
ultimately affecting the quality of phonations produced.
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‘Body-cover’ theory – ‘Cover’ explained
The ‘cover’ is the mucous membrane which sits on the ‘body’ and is comprised of
both the superficial lamina propria and overlying squamous epithelium. This ‘cover’ is
the vibratory layer of the vocal fold. The superficial lamina propria is particularly
important for its role in vibration. The biomechanics of vibration rely on the superficial
lamina propria’s extracellular matrix (ECM) protein composition, the concentrations of
proteoglycans and glycosaminoglycans and their relative densities, to maintain the
pliability and elasticity necessary for phonation.16 Of these, the glycosaminoglycan,
hyaluronic acid, has been identified as having the greatest influence on maintaining the
viscoelasticity properties necessary for normal phonation.16-18
The biomechanics involved in the production of phonation underly the importance
of appropriate structure and pliability of the vocal folds. The cover portion of the vocal
fold vibrates over the body in a mucosal wave motion to create phonation.19 During
normal phonation, the vocal folds will oscillate and collide in an incredible range of 20Hz
to 3kHz, with an average fundamental frequency of an adult male around 100 Hz and an
adult female at 200 Hz.20,21 Unlike other specialized stratified squamous epithelium, the
vocal cords withstand cyclical tensile, shear, and impact tissue stress requiring continual
repair of the epithelium while maintaining its viscoelastic properties.22 An in depth
discussion on the mechanism of phonation including acoustics and biomechanics of vocal
fold oscillations is beyond the scope of this project. However, it should be noted that
finding an optimal treatment for vocal fold scarring requires a robust replacement able to
withstand the stresses of normal vibratory function.
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Pathophysiology of Vocal Fold Scarring
Despite the vocal folds impressive ability to heal, both normal and impaired
healing can lead to fibrosis of the vocal folds. While incidence and prevalence statistics
of vocal fold scarring is still lacking in the literature, vocal fold scarring and resultant
dysphonia has been studied for nearly 30 years.23 The pathophysiology of vocal fold
scarring has been illuminated in this time.
Causes of vocal fold scarring can be divided between two sources of damage:
trauma (e.g. phonotrauma from overuse, intubation, iatrogenic during surgery) or
inflammation (e.g. laryngitis, exposure to environmental irritants, laryngopharyngeal
reflux).24-30 In particular, vocal fold damage and scar formation due to squamous cell
carcinoma of the vocal fold and iatrogenic damage to the vocal fold during laryngeal
cancer resection can lead to significant scar formation.31
The microstructure of the vocal fold scar tissue has been of particular interest in
scar formation and treatment options. Histologic analysis of scarred folds has
demonstrated fibrotic changes in the extracellular matrix (ECM) particularly evident in
the lamina propria. These include deposition of excessive and disorganized collagen, loss
of elastin fibers, and changes in hyaluronic acid, fibronectin, and procollagen
densities.25,32-34. Collagen deposition and loss of elastin affects the mechanical properties
of the vocal fold, such that the cover layer stiffens and is unable to form a mucosal wave
impairing optimal vibration. Additionally, severe scar formation can undergo a cicatricial
process which leads to loss of vocal fold bulk in the affected fold that then causes glottal
insufficiency, such that the two folds are not able to collide.35,36 Together, these changes
to the vocal fold ECM manifest into difficulty phonating properly and appear clinically as
dysphonia.
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Current Literature for Scar Treatment
Together with the longstanding interest in the pathophysiology of vocal fold scars,
treatment options have been studied. Non-surgical interventions to improve dysphonia
include voice therapy. As a treatment it has had questionable success for non-organic
vocal dysphonia, such as with phonotrauma, but lacks evidence of efficacy for severe
vocal fold scarring.37-39
Surgical intervention has instead become the treatment regimen of choice for
severe scar tissue. Phonosurgery, microsurgery of the vocal folds to improve vocal
qualities, was the initial surgical option for vocal fold scarring and has continued to
improve with technological advancements, yet has inconsistent, often suboptimal
results.37,40 Additionally, surgical interventions have extended recovery periods, up to one
year, in order to achieve maximum effect with ongoing voice rest and rehabilitation
needed during recuperation.38,41 The requirements of recuperating from cold steel surgical
interventions with unpredictable, unsatisfactory results following scar resection has
created fertile ground of research in laryngology to find a more suitable treatment option.
Treatments involving injectable therapies to bolster results of surgery have been
studied concurrently with direct surgical intervention. These treatments have many
benefits in common, including the ability to provide in-office injections, ease of use, costeffectiveness, and availability of the injectable substances.42 Steroid injections directly
into the scarred vocal fold is a common first-line treatment for vocal fold scars. Steroids
are thought to control the inflammatory response by modifying cytokine secretion, but
there is limited evidence that they are an effective treatment for severe vocal fold
scarring.43-45 Furthermore, inflammation and wound healing can cause contracture of the
vocal fold, as mentioned previously, which can be worsened by the steroid’s atrophic
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effects on the vocal folds.45 Research into injectables materials that ameliorate these side
effects has steadily continued. Biologic materials including fascia, autologous fat, and
collagen, commonly used for augmentation and medialization of the vocal fold, have
been attempted to improve vocal scarring with minimal desired effects.46-49 As such,
while steroid injections and biologic material injections currently make up the common
treatment for vocal fold scarring, they leave much to be desired in terms of outcomes.
Bioactive chemicals found in the normal ECM of the vocal cord mucosa have also
been studied extensively as a treatment for vocal fold scarring. The glycosaminoglycan,
hyaluronic acid (HA), was initially found to be important for scarless wound healing in
fetuses, and given its active properties functionally and biologically has become an active
area of research and treatment modality.50-52 HA within the vocal fold minimizes the
mechanical stress of the folds during oscillations, acting as a shock absorber and tissue
damper.53,54 HA also has immunomodulating properties important for cell migration and
wound healing.50 HA has been used to prevent vocal scar formation following injury.55-57
Finck et al. 2010 reported on long-term outcomes of esterified HA gels implanted
following surgical resection of scar, with improvements in vocal fold videostroboscopy
assessments, including vibration amplitude, mucosal wave symmetry, glottic gap, and
voice quality assessments.58 Provided its perceived and documented benefits, future
therapies that incorporate HA as a component are highly likely.
The development and growth of regenerative medicine–constructing tissue to
replace or repair existing tissue–has led to the creation of sophisticated materials that can
be used to repair scarred vocal folds and regenerate the ECM microstructure. Synthetic
polymer scaffolds, cell transplantation, growth factor injections, and other state-of-the-art
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biomaterials have created additional opportunities to find a solution for regenerating the
larynx with varying success. 59-63 These studies are too numerous to include here,
however cell therapies within the folds have included pluripotent stem cells,
mesenchymal stem cells, and fibroblasts. Pre-clinical in vitro animal studies have shown
that adipose-derived mesenchymal stem cells have multiple applications within the
larynx, including becoming cartilage-like grafts, developing into lamina propria,
epithelium, and ECM.64-66
Cell and biologic therapies have shown the greatest promise, with some therapies
advancing to human clinical trials. Hirano et al. 2017 injected hepatocyte growth factor
into the vocal folds for four weeks with assessment at six months post-procedure. They
found treatment to be safe and effective, with significant improvement in objective
(maximum phonation time, vocal fold amplitude) as well as subjective (voice handicap
index-10 [VHI], voice grading and expert voice quality assessment) findings.67 Ma et al.
2019 injected autologous cultured fibroblasts in patients with vocal fold scarring and agerelated atrophy, these patients then received graded assessments at four, eight, and twelve
months. Treatment groups had significantly improved mucosal waves at four and eight
months, and improved vocal quality, assessed by professional voice raters, at twelve
months.68 Hertegård et al. 2020, injected bone-marrow derived autologous mesenchymal
stem cells following scar resection. This also showed safety and efficacy improving
vibration and elasticity at one year, along with improvement in subjective patient
surveys.69 These studies have focused on the introduction of a single component to
improve the vocal fold repair through immunomodulation of the healing process through
either direct introduction to scar tissue or following scar tissue resection.

8
Introduction to COVR
This laboratory instead proposes a novel approach of replacing the entire vocal
fold mucosa. To this end, we developed the cell-based outer vocal fold replacement
(COVR) implant, a tissue-engineered treatment designed to be implanted directly
following removal of native scarred vocal folds.70 The COVR implant is created from a
multipotent adipose-derived mesenchymal stem cell tissue embedded within a threedimensional fibrin gel scaffold. Previous work by this laboratory has shown the
epithelization by adipose-derived stem cells to create a bi-layered structure similar to the
epithelium and lamina propia.64 Additionally, this structure was found to exhibit
biomechanical and functional vibration mechanics suitable for vocal fold structure
replacement.65
Long et al. 2018 showed initial success of COVR implantation within an in vivo
rabbit study.70 This pilot study involved unilateral cordectomy of sixteen rabbits within
three treatment arms: fibrin glue alone, autologous mucosal replants of vocal fold tissue
and COVR implants. Four weeks after surgery the rabbits were euthanized, and larynges
harvested. The COVR treatment group achieved excellent graft implantation,
regeneration of vocal fold epithelium and lamina propria, and induced phonation as
determined histologically and by mucosal wave symmetry, respectively. Importantly, at
this timepoint the COVR ECM structure remained immature with impaired vibration
compared to the mucosal transplant treatment group.
The structure of the ECM, particularly changes to the fibrin and collagen
deposition within the lamina propria, have been found to reflect the degree of damage
and healing of the vocal folds. Previous COVR implant larynges were harvested at four
weeks and had immature ECM with mature elastic fibers not identified within the implant
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sites and diminished mucosal-polysaccharide staining when compared to mucosal
replants. It is possible that additional post-operative recovery time would allow for ECM
maturity and therefore regenerate a more normal composition.
Statement of Purpose and Specific Aims
The goal of this project was to identify the intermediate and long-term outcomes
of human-derived stem cell COVR implants within animal models. We included a large
animal model with a COVR implant developed using human stem cells and long-term
follow up to create realistic conditions of the COVR implant as a future human
therapeutic.
We hypothesized that both intermediate and long-term implantation of human cell
based COVR will also lead to regeneration of the vocal fold epithelium and lamina
propria and establish an ECM structure that approximates normal ECM structure.
AIM 1:
The assessment of the development of the epithelium, lamina propria, and the
ECM following intermediate-term implantation of COVR in vocal folds through
histology. We determined intermediate effects in COVR implants compared to individual
components of the COVR implant by assessing active factors in wound healing, such as
white blood cell presence, collagen and fibrin deposition, and glycosaminoglycan
incidence.
AIM 2:
To develop a large, voicing animal model for the assessment of longer term
COVR implantation to ultimately determine the effect on voice quality following COVR
implantation.
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METHODS
All animal activities were done in accordance with the Institutional Animal Care
Committee, following USDA guidelines for animal ethics and under veterinarian
supervision. The protocols of the studies were submitted to and approved by the UCLA
Animal Research Committee IRB.
COVR development
Human adipose-derived stem cells (hASC) were used to construct the COVR
implants. For development of rabbit COVR gels, rabbit fibrinogen was used, and pig
fibrinogen was used for pig COVR gels. Otherwise, production of COVR gel implants
were equivalent for both groups. Size of the implant was adjusted for the two species,
with rabbits receiving one-half a gel per vocal fold, and pigs receiving a whole gel.
As described previously, COVR development used animal-specific fibrinogen,
bovine thrombin, and hASC in suspension were mixed in a 4:1:1 ratio.70,71 Final hASC
content was of 6x105 cells/gel. The mixture was placed within a 12 mm Corning
Transwell culture insert to create fibrin gels embedded with ASC. Total volume was 900
ul per gel. Following gelation, additional hASC were pipetted onto the surface to emulate
the epithelial layer. The insert conserved the air interface on the hASC covered surface of
the gel intended to become the epithelial layer and media diffused through the remainder
of the gel. The COVR gels were incubated and maintained with culture medium
containing 10% fetal bovine serum and 10 ng/mL epidermal growth factor for 2 weeks.
Media was replaced every 2-3 days.
Decellularized Gel (DECELL) development
DECELL production was identical to initial COVR development. Following the 2
weeks of incubation, the COVR gel was placed in sterile Sodium Dodecyl Sulfate (SDS)
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1% solution on a shaker for 3 days, with daily solution changes. DECELL gels were then
washed for 24 hours with sterile saline prior to implantation.
Rabbit Laryngeal Surgery and COVR Implantation
49 New Zealand white rabbits, weighing 3-3.5 kg, underwent survival surgeries as
described previously.70-72 Anesthetization was achieved with combined mask and
chemical induction and maintenance on isoflurane. In brief, a vertical midline neck
incision was made to expose the larynx and trachea. A lower tracheostomy was
performed, and pediatric endotracheal tube was placed to maintain intra-operative
anesthesia. A laryngofissure through the midline thyroid cartilage exposed the vocal
folds. A cordectomy meeting the definition of a European Laryngological Society type II
was then conducted.73 The membranous cover layer of the vocal fold was resected
bilaterally by sharp dissection, with reflection of the epithelium and lamina propria to
superior and inferior edges of the vocal fold confirmed with exposure of the
thyroarytenoid muscle. Surgery was performed by the same surgeon in all cases.
Intraoperatively, the COVR implant was divided in half, with one half of the gel placed
on either vocal fold for the rabbit implantations, while maintaining appropriate
directionality of the developed COVR epithelial layer.
Immediately following surgical resection, rabbits received one of four treatments:
11 rabbits received hASC Injection directly into the remaining vocal fold structure,
receiving approximately 600,000 cells per side. 13 rabbits received COVR implants,
which were placed superficially over the thyroarytenoid muscle with the bulk of the gel
overlying the medial vocal fold. The COVR implant was then secured with sutures at the
corners of the gel. 12 rabbits received DECELL implants which were placed similarly. 12
rabbits in the SCAR treatment group had removal of the mucosal membrane only with
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cupped forceps and served as injured controls. Care to achieve appropriate hemostasis
was taken. Following the intervention, the rabbits received corticosteroid, proton pump
inhibitor, and subcutaneous pain medication for 48 hours in addition to a 10-day
antibiotic course. At 6 weeks the rabbits were euthanized, and larynges were harvested.
Two of the animals died prematurely. One COVR group animal died 2 days after
implantation. At autopsy, food was found at the laryngeal inlet, and cause of death was
attributed to aspiration and asphyxiation. One animal in the SCAR group died
immediately post-operatively and was attributed to ketamine reaction. Further animals
did not receive this medication.
Pig Laryngeal Surgery and COVR implantation
Three Yucatan Mini pigs, aged 12-18 weeks and weighing 13-26 kg, were
anesthetized via combined masked and chemical induction with intraoperative
maintenance of isoflurane. The preferred transoral endoscopic approach for intervention
under direct visualization was attempted initially. Both the SCAR and hASC Injection
treatments were successfully completed via direct endoscopy. However, the anatomy of
the pig’s airway, particularly the pig’s deep larynx and narrow pharynx, made it difficult
to perform the fine physical maneuvers required for optimal positioning of COVR
implantation. The COVR implantation was converted to an open transcervical approach
as described in the rabbit surgery above. Surgical interventions of the vocal fold mucosa
were unilateral with a single, unaltered COVR gel implanted to the vocal fold. The
remaining vocal fold was unaltered and served as control vocal fold.
Following surgical dissection, the three pigs were each placed into a treatment
group. One pig received hASC Injection of approximately 600,000 cells in the injured
vocal fold, to provide equivalent cell number to the COVR. One pig received no
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treatment and served as a SCAR control. The last pig received the COVR implant placed
superficially with four sutures at the corners of the COVR implant to secure it in position.
At 6 months, terminal surgery included intraoperative in vivo phonation recorded via
high-speed camera. Pigs were subsequently euthanized, and larynges were harvested.
The COVR pig developed rapid neurologic decline and death at 6 weeks post-op.
On autopsy, the cause of death was determined to be an endemic porcine infection, most
likely a strain of Streptococcus suis. The pig had been immunosuppressed which was
thought to be a factor in its death. Because of the circumstances, in vivo phonation was
not available for this animal.
Microscopy
All rabbit larynges were formalin-fixed, paraffin-embedded, and sectioned.
Histological sections of the bilateral vocal folds were stained with hematoxylin and eosin
(H&E), MOVAT pentachrome (MOVAT), Anti-Human Leukocyte Antigen (HLA),
Anti-Bovine Serum Albumin (BSA), and 4′,6-diamidino-2-phenylindole (DAPI).
MOVAT stain is commonly used for connective tissue staining and includes a mix of five
stains: alcian blue, Verhoeff hematoxylin, crocein scarlet combined with acidic fuchsine
and saffron.
Light Microscopy
The H&E and MOVAT pentachrome sections were evaluated by light microscope
to assess the presence of collagen, glycosaminoglycans (GAG), fat, fibrin, infiltrate, and
irregular epithelium. Infiltrate was described as none, present, or infiltrate plus dependent
on the amount of white blood cells found within the section. Secondary review of select
slides were reviewed by a blinded head and neck pathologist for histological
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confirmation. The COVR group rabbit that died prematurely following the implantation
was not included in the results or analysis.
Fluorescent microscopy
Rabbits were stained with DAPI fluorescent dye, used to visualize nuclei and
additionally dyed with either HLA or BSA. The hASCs were confirmed to stain and
fluoresce with HLA. As the COVR and hASC Injection treatments both used human
derived stem cells, HLA fluorescence was used to determine survivability of the hASCs.
BSA served as a negative control.
Nonlinear scanning laser microscopy (NSLM)
NLSM imaging can capture both second harmonic generation (SHG) and twophoton fluorescence (TPF). SHG imaging captures images based on the scattering of
photons that are collected, while TPF uses fluorescent emissions for image detection and
capture.74 NLSM has been previously used in pig vocal folds to visualize, quantify, and
define orientation of both Type I and Type III collagen, as well as elastin.75,76 For NSLM
imaging unstained, paraffin fixed slides of pig vocal fold tissue were created from both
the treated and untreated cords of each pig. NSLM imaging was performed on a custom
Leica Sp8-MP-DIVE confocal microscope system with imaging of both SHG and TPF
image detection and capture recorded simultaneously. SHG was used to visualize
collagen and TPF to visualize elastin. Images were collected using a 20x dry lens, with
10 percent overlap of images with live imaging averages during acquisition. SHG was
captured at 400-420nm and TPF was captures at 497-567 nm wavelengths. Microscope
imaging and capture details, including power of SHG and TPF lasers, line and frame
averages, and acquisition depth were based on trial and error. The hASC Injection and
SCAR treated pig vocal folds were imaged to include all scannable section from the
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epithelium to just beneath the transition of the musculature, capturing the entirety of the
vocal fold cover layer. These pig cover layers areas of interest were confirmed with H&E
and MOVAT pentachrome stained sections. The COVR treated pig vocal fold sections
were imaged in their entirety.
We performed a modified approach to the imaging and data analysis initially
described in in Miri et al. 2012.75 Specimen imaging of the mucosa layer included all
epithelium and lamina propria layers up to and including the interface of the
thyroarytenoid musculature. Image analysis was completed using Image J software. The
images were processed through Image J using the preinstalled automated image
thresholding and then processed by the automated percent area fraction programs and
outputs were recorded. Superficial and deep LP layers were distinguished based on
anatomical relationships to epithelial and musculature borders, respectively, as described
in the literature.12,77 Vocal fold images that were either purely musculature or between
confirmed superficial and deep lamina propia layers were labeled indeterminant. Raw
images were processed manually to include regions of interest in the superficial and deep
lamina propria to exclude any portion of epithelium or musculature within the captured
images. A representative image of the SHG and TPF NLSM captured images and the
Image J processed regions of interest can be found in Figure 2.
Collagen and elastin levels, as reflected by the percent area fraction, in both the
superficial lamina propia (SLP) and deep lamina propria (DLP) were recorded. A
collagen-to-elastin ratio, reflecting percent area fraction collagen divided by percent area
elastin for each image was also collected. Direct intra-animal comparison between treated
and untreated vocal fold of each pig was analyzed. Representative images of the H&E,
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MOVAT pentachrome, and NLSM imaging of collagen and elastin in the SLP and DLP
layers can be found in Figure 3.

RESULTS
Aim 1 Results:
Light microscopy representative images of rabbit vocal fold sections stained with
H&E and MOVAT pentachrome can be found in Figure 4. Representative fluorescent
microscopy images of rabbit vocal folds stained with HLA + DAPI and BSA + DAPI can
be found in Figure 5.
COVR (n=12):
Collagen was present in 50 percent of the sections and was generally described as
either thin or wavy and rarely thick and bundled. Appreciable fibrin was present in only
17 percent of vocal folds, was found deep to the epithelium, was small, with well-defined
borders, and slightly eosinophilic. GAGs were found in 50 percent of the sections and
was present throughout the vocal fold sections. Fat was present in 25 percent sections.
Infiltrate was found in 50 percent of the sections, all infiltrates were described as present
with no infiltrate plus noted. Irregular epithelium was noted on 25 percent of sections. All
twelve sections of the COVR group rabbits stained positive for HLA and negative for
BSA.
DECELL (n=12):
Collagen was present in 67 percent and was described as wavy, aligned, and
occasionally thick and bundled. Fibrin was present in 67 percent of the sections. The
fibrin within the DECELL sections were large, stained darkly eosinophilic, had clearly
defined edges, and were located at or near remnant sutures. In only one section, 8
percent, had GAG stain positive within the vocal folds. Fat was not present in any

17
laryngeal sections. Infiltrate was present in 83 percent of sections with two sections, 17
percent, described as infiltrate plus. Irregular epithelium was noted in 25 percent of
sections. No sections of the DECELL group stained positive for either HLA or BSA.
hASC Injection (n=11):
Collagen was present in 82 percent of sections and was primarily described as
deep, dense, and bundled. Fibrin was present in 18 percent of sections and described as
amorphous and slightly eosinophilic. In only one section, 9 percent, stained positively for
GAGs. Fat was present in 55 percent of sections. Infiltrate was present in 45 percent of
all sections, with 27 percent described as infiltrate plus and the remaining 18 percent as
infiltrate present. Irregular epithelium was noted in one section, 9 percent. All twelve
hASC Injection sections stained positive for HLA, no section stained positive for BSA.
SCAR (n=12):
Collagen was present in 83 percent of the sections and was primarily described as
heavy and disorganized. Fibrin was present in one section, 8 percent, and described as
amorphous and slightly eosinophilic. GAGs were stained positive in 25 percent of the
sections. Fat found in 42 percent of sections. Infiltrate was noted in 42 percent, with no
sections described as infiltrate plus. Irregular epithelium in was found in 17 percent of
sections. No sections of the SCAR group stained positive for either HLA or BSA.
Aim 2 Results:
Nonlinear scanning laser microscopy (NLSM) values of percent area fraction of
collagen and elastin, and the calculated collagen-to-elastin ratio of each Pig vocal folds in
the three treatment arms, hASC Injection, SCAR, and COVR, were compared directly.
hASC Injection treatment pig:
hASC Injection treated vocal folds (hASC) yielded 38 total images which were
categorized as superficial lamina propia (SLP) (n=12), deep lamina propria (DLP) (n=6),
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and indeterminant lamina propria (n=20). The control vocal fold (CTL) yielded 42 total
images: 6 SLP images, 6 DLP images, and 30 indeterminant images. Percent area fraction
findings of both elastin and collagen, and collagen-to-elastin ratio data found in Figure 6.
SLP and DLP percent area fractions of both the CTL and hASC treated vocal
folds were compared. The CTL fold had significantly greater collagen area fraction in
the DLP than in SLP (10.1±3.6 and 5.0±2.5%, p<0.01 two-way ANOVA). The collagento-elastin ratio was significantly higher in the DLP than the SLP (0.40±0.07 and 0.21
±0.31, p<0.01 two-way ANOVA). The hASC vocal folds had significantly increased
collagen area fraction in the SLP than DLP (27.1±6.4% and 14.6 ±4.6%, P<0.001 twoway ANOVA). The hASC Injection collagen-to-elastin ratio was significantly greater in
the SLP than in the DLP (1.2±0.3% and 0.2±0.08%, p<0.001 two-way ANOVA). Elastin
was not significantly different between the SLP and DLP in either the CTL or hASC
vocal folds.
Comparisons between the CTL and hASC treated vocal fold SLP and DLP were
analyzed. In the SLP, collagen percent area fraction was significantly greater in the hASC
group than in the CTL fold (27.1±6.4% and 5.0±2.5%, p<0.001 two-way ANOVA).
Additionally, the SLP collagen-to-elastin ratio was greater in the hASC Injection fold
than in the CTL fold (1.2±0.3% and 0.2±0.08%, p<0.001 two-way ANOVA). There was
no significant difference in the elastin percent area fraction in SLP. Within the DLP, the
hASC Injection treated vocal fold had a higher collagen percent area fraction than the
CTL fold, that was approaching but did not reach significance (p = 0.07, two-way
ANOVA). However, the collagen-to-elastin ration in the hASC was greater significantly
greater than the CTL fold DLP (0.5±0.1 and 0.04±0.07%, p<0.05 two-way ANOVA).
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SCAR treatment pig:
Scarred vocal folds (SCAR) imaging yielded 54 total images, 18 SLP, 20 DLP,
and 16 indeterminant images. CTL yielded 58 total images, 18 SLP, 13 DLP, and 27
indeterminant images. Percent area fraction findings of both elastin and collagen, and
collagen-to-elastin ratio data can be found in Figure 7.
Within the CTL vocal fold, the SLP had significantly increased collagen percent
area fraction (12.9±4.6% and 4.5±2.2%, p<.001 two-way ANOVA) and elastin percent
area fraction (31.0±9.2% and 16.1±4.2%, p<0.001 two-way ANOVA) compared to the
DLP. The collagen-to-elastin ratio in the SLP was increased compared to the ratio DLP
but did not reach significance (0.4±0.2 and 0.3±0.2, P = 0.054 two-way ANOVA).
Pig 2’s SCAR treatment had significant differences in both the superficial and
deep lamina propia. Compared to CTL the SLP elastin was significantly lower
(21.0±5.9% and 31.0±9.2, p<0.001 two-way ANOVA). The collagen-to-elastin ratio was
also significantly increased in the SCAR SLP than in the CTL fold (0.7±0.3% and
0.6±0.2, p<0.001 two-way ANOVA). There was no significant difference in the collagen
levels between the SCAR and CTL within SLP. In the deep lamina propia, the SCAR
fold had increased collagen percent area fraction (12.8±5.1% and 4.5±2.2%, p<0.001
two-way ANOVA). The collagen-to-elastin ratio was also significantly increased in the
SCAR fold compared to the CTL (0.7±0.3% and 0.3±0.2, p<0.001, two-way ANOVA).
There was no significant difference in DLP elastin levels between the SCAR and CTL
folds.
COVR treatment pig:
COVR treated vocal folds (COVR) imaging yielded 1048 images, 64 SLP, 28
DLP, and 956 of the remaining images were indeterminant or contained only
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musculature. CTL yielded 334 total images, 26 SLP, 24 DLP, 284 were indeterminant or
musculature only. Percent area fraction findings of both elastin and collagen, and
collagen-to-elastin ratio data can be found in Figure 8 Additionally, representative H&E
and MOVAT pentachrome stained sections and NLSM imaging of both control and
COVR treated vocal folds can be found in Figure 9.
Within the CTL fold, the collagen percent area fraction within the SLP was
significantly higher than the DLP (21.4±9.8% and 11.2±4.5%, p<0.001 two-way
ANOVA). The elastin percent area fraction was significantly greater in the DLP than the
SLP (20.7±6.9% and 11.3±10.2%, p<0.001 two-way ANOVA). The collagen-to-elastin
ratio was significantly larger in the CTL SLP than the DLP (4.4±4.7% and 0.7±1.1%,
p<0.001 two-way ANOVA). Within the COVR folds, there were no significant
differences in the percent area fraction of either the collagen and elastin, nor in the
collagen-to-elastin ratio between the SLP and DLP.
Pig 3’s COVR treatment had significant differences in both the superficial and
deep lamina propia, compared to the CTL fold. Comparing the SLP, the collagen was
significantly increased in the CTL fold compared to the COVR fold (21.4±9.8% and
8.1±3.4%, p<0.001 two-way ANOVA). The elastin in the COVR SLP was also higher
than in the CTL (17.7±8.6% and 11.3±10.2, p<0.01 two-way ANOVA). The collagen-toelastin ratio was significantly larger in the CTL SLP than the COVR SLP (4.4±4.7% and
0.7±1.1, p<0.001 two-way ANOVA). The DLP collagen percent area fraction was
significantly larger in the COVR group than the CTL (11.2±4.5% and 7.5±3.3%, p<0.01
two-way ANOVA). There was no significant difference between the COVR and CTL
DLP with respect to the elastin and collagen-to-elastin ratio.
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A comparison image of percent area fractions and collagen-to-elastin ratio of the
superficial layers of all three pigs can be found in Figure 10.
DISCUSSION
Dysphonia has a sizable health care cost burden and has significant negative
effects in the lives of those affected. Optimal treatment for the disruption of the vocal
fold microstructure in dysphonia caused by severe vocal fold scarring remains elusive
and attempts at improving the healing process to improve vocal quality has proved
challenging. Surgical resection and cold steel interventions often redevelops scar tissue
through normal wound healing, while injectable therapies of biologic and bioactive
materials have led to limited success in the development of appropriate extracellular
matrix and improved functional outcomes.
Despite decades of attempts, scarred vocal folds remain difficult to repair.
Regenerative medicine techniques to restore native tissue or replace structures with
functionally identical tissue, provides an avenue of therapeutics that may best address the
challenge of vocal fold scarring. Multiple cell and biologic therapies have shown
preclinical success, with three recent human clinical trials demonstrating encouraging
safety profiles and improved objectively gathered results.67-69 Overall, subjective
improvements in vocal quality, as reported by patients on the vocal health index (VHI)
has also been encouraging, though less consistent. In patients who received injected
autologous fibroblasts as treatment, VHI improved, but failed to reach statistical
significance.68 In patients who received autologous mesenchymal cell injections, only
half of them showed improvement on the VHI.69 Some stem cell injections lack
persistence, including some mesenchymal stem cells that have been noted to die within
24 hours following injection. Furthermore, treatment is limited by scar size, such that
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larger defects cannot be fully regenerated by injection.78-80 Together, this provides a
limited therapeutic treatment window and time-limited effectiveness of immune
modulation. The approach we take on replacing the damaged vocal fold mucosa entirely
with the COVR implant directly addresses the concerns raised by these clinical trials.
Aim 1 - Histology of COVR and Components
Collagen
We compared the histologic findings of the intermediate-term implantation of
COVR, and the COVR components, a decellularized fibrin matrix and the human
adipose-derived stem cells within rabbit vocal folds to elucidate the benefits and method
of action that the COVR implant has in wound healing and scar formation. When
comparing hematoxylin and eosin, as well as Movat pentachrome stained sections,
patterns emerge within the healing cycle. Overall analysis of the rabbit laryngeal section
histology provide evidence that intermediate term COVR implantation inhibits scar
formation when compared to the separated COVR components, decellularized scaffold
and direct hASC Injections, as well as non-treated scar control. On review, the COVR
and DECELL group had notably fewer total sections stain positively for increased
collagen than the hASC Injection and Scar treatment groups. The collagen in both the
DECELL and COVR groups was also more often described as thin and wavy, while the
hASC Injection laryngeal sections were more often described as thick and bundled or
disorganized, the hallmark description of histologic fibrosis.18 It is possible that the wavy
collagen will continue remodeling to become organized and cross-linked, functionally
normal collagen, however, scar tissue formation and collagen remodeling can take up to 2
months.25 Thus longer implantation and histological follow-up is required to confirm the
ultimate fate of this collagen. Nonetheless, the decreased collagen levels and favorable
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description of this collagen supports the finding that the COVR implant attenuates scar
tissue formation that is maintained after intermediate-term implantation.
Inflammatory Response
In comparing the inflammatory response, an infiltrative process was present in a
majority of the DECELL group and half or less of all sections in the COVR, hASC
Injection, and SCAR treatment groups. However, the hASC Injection and DECELL
groups had multiple sections described as having a continued robust white cell presence
at six weeks, while both the COVR and SCAR group both had no sections with this level
of immune response. The DECELL group’s inflammatory response raises the question of
an inflammatory response to the decellularization process. Indeed, residual SDS can
cause a severe inflammatory response, however, the infiltrate in our sections lacks the
encapsulation, giant cells, or hemosiderin-laden cells as previously described, making
this explanation unlikely.81 Instead, we propose that the lymphocytic reaction in the
DECELL group more likely resembles a foreign body immune response. Mesenchymal
stem cells have low immunogenicity, while fibrin as a standalone therapy and as a
medium for cell introduction, is known to promote faster wound healing through
angiogenesis, improved cell viability, proliferation and differentiation, and excellent
integration into surrounding tissue.82,83 Our data indicates that xenographic ASCs
implants maintain an immunomodulatory effect on surrounding tissue up to six weeks
and have an improved attenuating influence when embedded within a fibrin matrix than
when introduced into tissue by direct injection alone.
Glycosaminoglycans
As mentioned previously, the levels of GAGs in the vocal fold are critically
important for normal function. HA is the most abundant glycosaminoglycan in the folds,
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is a reliable marker of good healing in the vocal folds, and stains with the pentachrome
used in this study.33 The COVR group sections stained positively for HA in six of the
twelve sections sections and the SCAR group stained positively for HA in a three of
twelve sections, while the DECELL and hASC Injection groups both stained positively
for HA in only one section. The mechanism of GAG deposition, whether GAG derives
from the introduced ASC or native tissue, is unclear. Mesenchymal stem cells have HA
synthase and have been implicated in HA deposition in autologous bone marrow derived
MSC transplants in mice larynges and allogenic laryngeal mucosa derived MSC
transplants in canine larynges.84,85 Given that this was a xenographic treatment after
removal of native tissue, it is likely that introduced ASCs synthesize their own GAG, but
we cannot rule out stimulation of intrinsic GAG synthesis. The relative deficit of GAG in
the hASC Injection and DECELL groups may be explained by the prolonged incubation
during COVR development, during which GAGs may be synthesized and retained within
the scaffold. Additionally, the fibrin gel may play a protective role of the embedded cells,
limiting the lymphocytic response and clearing of the COVR cells, from which the
injected cells do not benefit. In either case, our data indicates that ASCs embedded within
a scaffold, but not directly injected into damaged mucosa, leads to improved GAG
deposition into the ECM at six weeks, reflecting improved wound healing and a more
normal ECM microstructure. This improvement of microstructure suggests improved
biomechanical properties which may have implication on functional outcomes of the
COVR treated vocal folds. The significance of the six COVR sections that did not stain
for HA is unclear, further studies are needed to confirm if the HA positivity has an effect
on voicing.
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HLA staining
Previous research in this laboratory has shown persistence of autologous adiposederived stem cells at four weeks embedded in fibrin gel scaffold.86 The rabbit fluoroscopy
imaging of positive HLA-staining cells indicates that xenographic implantation of human
ASC implanted in rabbit vocal folds persists up to six weeks whether embedded within a
fibrin gel structure or directly injected into the vocal fold. Additionally, there was a
greater HLA positivity in the COVR fluorescent images than in the hASC Injection
sections. There was no such positive staining in the DECELL gel structure. The increased
stem cell persistence in the COVR group compared to hASC Injection further supports a
protective benefit of the fibrin scaffold in overall cell survival and may suggests
increased proliferation of embedded cells, previously described in keratinocytes and
fibroblasts.87 Further analysis is required to understand whether these cells arise from
improved survivability of originally embedded cells, increased proliferation of cell
lineages, or a combination of both.
Fibrin
There were clear differences in the fibrin appearance and amount between the
treatment arms. The fibrin within the DECELL sections had well circumscribed, deeply
eosinophilic structures. When compared to the H&E laryngeal sections of the animal that
received COVR implant and died post-operatively, the DECELL larynges appeared
identical. We suspect then that the DECELL fibrin is retained fibrin from the implanted
gel structures. The fibrin in the COVR treated laryngeal sections had less clear gel
remnant and more closely resembled the fibrin found in both the hASC Injection and
SCAR groups. The COVR sections likely had a mixture of the remnant fibrin scaffold

26
and fibrin of residual wound healing, while the SCAR and hASC Injection was solely
lingering wound healing fibrin.
All treatment arms had presence of other findings, such as a presence of dispersed
fat cells and irregular epithelium, though there were too few cases to make any conjecture
on their implications, if any.
Aim 2 -NLSM imaging of pig vocal folds
Nonlinear scanning laser microscopy (NSLM), also called two-photon
microscopy or multi-photon microscopy, pulses two photons that simultaneously interact
with a molecule causing excitation, the resulting emission is then recorded as normal.88
Each of the NSLM photons are typically half the energy of a single-photon system, such
as in fluorescent microscopy, which minimizes the damage caused to tissue by higher
energy photons while simultaneously improving image detection.89 This allows for
excellent imaging of the vocal fold microstructure including the elastin and collagen
within the vocal folds, without the need to alter the tissues for imaging. Analysis of
treated vocal fold extracellular matrix collagen and elastin levels and calculated collagento-elastin ratio were compared to the control, unaltered contralateral folds in the three
treatment arms: hASC Injection, SCAR, and COVR implantation. Notably, there was no
attempt or intervention to enforce voice rest in these animals following their operation,
which is usual treatment in humans following vocal fold scar resection.
hASC Injection
The pig that received hASC Injection had control vocal folds with collagen,
elastin, and collagen-to-elastin ratios in the layer and concentrations distribution
described in the literature. The control fold had significantly greater collagen levels in the
deep lamina propria than in the superficial layer. The vocal fold that received hASC
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Injection had significantly increased collagen deposition in the superficial lamina propria
layer, similar to that seen in the rabbit histology, however this was not appreciated on
light microscopy of the pig vocal fold. The fibrosis indicates an increased inflammatory
response during healing, although no white blood cells were present in light microscopy
or in the NLSM images. This is likely due to the longer post-operative healing period
prior to laryngeal harvest. Voice rest during acute wound healing with gradual vocal fold
use has been noted to improve vocal fold wound healing and voice quality outcomes in
humans, while uncontrolled voice use worsens outcomes.90-92 We propose that the
unrestricted animal’s spontaneous phonations led to increased stress at the vocal fold
surface prior to epithelialization, which worsened acute wound healing and led to more
more fibrosed superficial lamina propria.
When comparing the hASC Injection treated and untreated vocal folds we found
significantly increased collagen deposition in the superficial layer and an increased and
non-significant though increased collagen deposition within the deep layer. Interestingly,
the magnitude of collagen increase in the superficial layer was much greater than in the
deep, suggesting that the hASC does have wound healing benefits that are more present
within the deep but not superficial layers of lamina propria. This is further evidenced by
an improved collagen-to-elastin ratio within the deep lamina propia and worsened
collagen-to-elastin ratio in the superficial lamina propria. The decreased fibrosis may
signal that the ASCs have their greatest immunomodulatory benefit at or near their
injection site, the thyroarytenoid muscle, and a weakened effect more superficially. There
were no significant differences between the elastin levels in the control versus treatment
vocal folds in either the superficial or deep lamina propria. This is consistent with
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previous findings of elastin levels returning to baseline at 6 months following injury.34
Overall, the increased collagen deposition indicates increased fibrosis and poor healing
following hASC Injection alone. Functionally, the superficial lamina propria is more
directly involved in sound production and vocal quality and we would expect a poorer
functional outcome in this pig.
SCAR Pig
The pig that received mucosal resection without intervention had an interesting
baseline vocal fold structure. NLSM imaging of the control fold showed significantly
increased baseline collagen levels and elastin levels in the superficial lamina propria, and
an increased collagen-to-elastin ratio that was also approaching significance. The scarred
vocal fold was more uniform, lacking any significant difference in total collagen or
elastin between the two lamina propria layers. Comparing the scar and control folds, the
elastin levels in the scarred fold was significantly decreased in the superficial lamina
propria. Within the deep lamina propria, the scarred fold showed significantly increased
collagen levels, as expected. Our findings support previously document decreases in
elastin levels in scarred folds and collagen deposition in the deep lamina propria.34,48
Moreover, the baseline findings in this animal’s control fold illustrate the importance of
evaluating collagen structure and organization, not purely overall levels, when
determining scar tissue in histology.
COVR Pig
The pig that received the COVR implant died six weeks after the intervention
from an indolent Streptococcus Suis infection that was exacerbated by postoperative
immunosuppression. NLSM imaging analysis of the control vocal fold identified
significantly increased collagen in the superficial layer and significantly increased elastin
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in the deep lamina propria, which we believe reflects injury to the control vocal fold. This
is not surprising as we transitioned to an open surgical approach during COVR
implantation which we may have led to some collateral damage, not seen in the other pigs
that underwent an endoscopic intervention.
Interestingly, the COVR treated vocal folds were more uniform, as there were no
significant differences between the superficial lamina propria compared to the deep layer.
While epithelialization occurs during COVR development, this data supports a delayed
division of the mucosal layers that occurs beyond six weeks following implantation.
Comparing the treated and untreated folds, the superficial lamina propria of the COVR
fold had significantly decreased collagen deposition, increased elastin levels, and an
improved collagen-to-elastin ratio than the control. While mature scar formation may
take up to a year in the vocal folds, postinjury collagen synthesis is greatest during the
first six weeks of healing, and the SHG imaging modality is sensitive to both Type I and
Type III collagen, which predominate early scar formation.25,34,75 Thus our data suggests
that COVR implantation improves wound healing at six weeks, which we expect will
improve longer durations of healing as well.
In the deep lamina propria, the COVR implant had increased collagen deposition
compared to the control fold. During COVR development, a layer of hASCs is added to
the superior, non-immersed surface of the gel, which becomes the epithelial layer. As this
animal had only six weeks of COVR implantation, we would expect continued
persistence of hASCs greater at the epithelium and superficial lamina propria, as seen in
the rabbit HLA histology. A greater number of bioactive stem cells would therefore have
improved healing effects within the superficial lamina propria and less of an effect within
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the deep lamina propria. In addition, initial healing and implant grafting would occur at
the juncture of thyroarytenoid musculature and COVR implant, which would help explain
the increased collagen deposition in the deep lamina propria. Although long-term COVR
implantation is needed to confirm that fibrosis indeed remains limited in the superficial
lamina propria with this therapy, our preliminary findings are encouraging. Furthermore,
additional methodologies are needed to understand the long term structural and functional
improvements that COVR treated larynges have on voice production and vocal quality.
Superficial Lamina Propria treatment comparisons
Contrasting the superficial lamina propria in the three treatment arms and their
respective controls further produced interesting findings. Contrary to expectation, the
hASC Injection pig, but not the SCAR pig, had a significantly increased amount of
collagen at six months. hASC cell injections as a treatment for vocal fold scarring leads
to improved collagen deposition in preclinical and clinical applications and is associated
with improvement in functional outcomes. A limitation of the NLSM imaging analysis in
this study is our reliance on quantifying the amount of collagen present, but not
describing nor account for the organization of the collagen fibers measured. As such, we
believe the percent area fraction of collagen, to infer levels of collagen, is a poor marker
of fibrosis if collagen organization is not taken into account. The calculated collagen-toelastin ratio is also heavily influenced by the collagen percent area fraction and was not
found to be a useful as a marker of fibrosis or comparison between animals. Instead, we
argue that decreased elastin is a more sensitive marker of fibrosis and improved healing
in NLSM imaging. In comparing elastin levels, we find the SCAR pig has the worst
outcome, as expected. The hASC Injection elastin levels are equivalent to control fold
levels and therefore suggest improved healing compared to scar. The COVR treatment
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had a significantly increased elastin level in the treated vocal fold also suggesting
improved healing, albeit at a shorter post-operative endpoint.
Comparisons of the deep lamina propria layers between the treatment and control
for the three treatment arms had increased collagen deposition for the SCAR and COVR
treated folds only. While statistically significant, vocal fold functionality and voice
production relies heavily on the cover portion of the vocal fold and less so on the body, to
which the deep lamina propria belongs. Thus, we expect that these increases in collagen
deposition would have minimal influence on voice quality and production, if any. We
suggest that future NLSM microstructure imaging focus on the superficial lamina propria,
and intermediate lamina propria where applicable.
Our preliminary findings suggests that the COVR implant, as a complete mucosal
replacement, improves overall wound healing with decreased fibrosis and intermediateterm ECM microstructure. This histologic analysis is limited by the subjective nature of
image analysis and the imperfect method of translating images to an absolute value; thus,
biochemical analysis is underway of the rabbit harvested larynges. Through enzymatic
cell digestion of all harvested rabbit vocal fold sections, we hope to identify cytokine,
mRNA, and ECM components and determine absolute quantitative values of
glycosaminoglycans, collagen, and fibrin, to correlate with the imaging analysis
performed here. Together, this will better elucidate the method of actions of the COVR
components, particularly the hASC’s role in immunomodulation and wound healing.
Additionally, ECM collagen and elastin levels within the pig laryngeal sections will be
identified and quantified by cell digestion to correlate with the imaging data presented
here.
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It remains to be seen if the histological improvements in the rabbit and pig
laryngeal sections translate to functional improvement following COVR implantation.
This laboratory is currently pursuing additional methods of analysis of pigs involved in
this study. Pig spontaneous in vivo phonations were recorded prior to their operations and
during the weeks to months following their interventions until their termination. During
the terminal surgery, the animals underwent induced in vivo phonation during which we
recorded the sound production and concurrent high-speed video recordings of the vocal
folds, with the notable exception of the COVR pig. These high-speed video recordings
will be analyzed for stroboscopy and mucosal wave analysis, commonly used methods of
vocal fold functional assessment both clinically and in animal research. The acoustic
analysis of the audio recordings at various timepoints pre- and post-surgery, will allow us
to determine what acoustic improvements, if any, occur following each intervention and
how these change over time. It is the hope of this laboratory to create a robust voicing
animal model for COVR implantation to advance this treatment as a therapeutic option
for patients.
CONCLUSION
Animals that received COVR, a human-derived adipose stem cell-based gel
implant, better regulate healing and scar development following intervention than those
which received cells only, fibrin gel only, or were scar controls. In rabbits, COVR
implantation promotes improved healing and decreased scarring at six weeks, as
supported by the increased hyaluronic acid deposition and decreased collagen
development. Xenograph ASCs grafts persist weeks and have continued
immunomodulatory effects up to six weeks following implantation. ASC
immunomodulatory effects are increased effects when embedded in a fibrin gel than
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when directly injected into damaged vocal folds. Decreases of overall elastin levels are
more sensitive marker of fibrosis in non-linear scanning microscopy imaging than
increases in collagen levels. Further research is needed to determine if histologic
improvement translates to improved functional improvements.
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